AZ starts enrollment in Phase III COVID-19 vaccine trial

AstraZeneca announced it has initiated enrollment for its 30,000-subject Phase III clinical trial for its COVID-19 vaccine candidate AZD1222. Testing will involve participants being given either a placebo or two doses of the vaccine four weeks apart.

Full Story: Reuters (8/31)